Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Software can be a medical device. Can it also be a drug?
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.